Loading…
PBM
Psyence Biomedical Ltd
NASDAQ· Healthcare· Biotechnology· CUSIP 74449F407
$4.21-2.32%Price as of Aug 29, 18:49 UTC · updated once a day, after the close
Key metrics
- Market cap
- —
- P/E
- —
- Forward P/E
- —
- P/B
- 0.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$12.56
- ROE
- -58.62%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.67
- 52-week high
- $216.41
- 52-week low
- $1.92
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $5.56 | $29.41 | $659.38 | $216,562.50 | |
| P/E | — | — | 0.9x | — | — |
| P/B | — | 0.8x | 0.4x | — | — |
| EPS | — | $32.76 | -$14,274.29 | -$940.02 | |
| ROE | — | -40.94% | 15.05% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ADVBAdvanced Biomed Inc. | $9.70 | 2.4x | 1.5x | — | 71.33% | $16.03M |
| ALTAltimmune, Inc. | $3.19 | — | 1.3x | — | -28.88% | $620.51M |
| BIIBBiogen Inc | $228.69 | 40.7x | 1.8x | — | 4.58% | $33.79B |
| CBIOCrescent Biopharma Inc | $17.75 |
About the company
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
- 12
- Toronto, Canada
Company description provided by Yahoo Finance.